Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial (Q42232023)

19 October 2017

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial (English)

1 reference

19 October 2017

phase I clinical trial

0 references

type-1 diabetes

0 references

phase II clinical trial

0 references

0 references

1 reference

Olivier Bourron

5

0 references

Michelle Rosenzwajg

object named as

Michelle Rosenzwajg

8

0 references

David Klatzmann

object named as

David Klatzmann

10

0 references

author name string

Agnès Hartemann

1

1 reference

19 October 2017

Gilbert Bensimon

2

1 reference

19 October 2017

Christine A Payan

3

1 reference

19 October 2017

Sophie Jacqueminet

4

1 reference

19 October 2017

Nathalie Nicolas

6

1 reference

19 October 2017

Michèle Fonfrede

7

1 reference

19 October 2017

Claude Bernard

9

1 reference

19 October 2017

8 October 2013

1 reference

The Lancet: Diabetes & Endocrinology

19 October 2017

1 reference

19 October 2017

1

1 reference

19 October 2017

4

1 reference

19 October 2017

295-305

1 reference

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Immune intervention in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Expansion of human regulatory T-cells from patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Interleukin-2 and regulatory T cells in graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Central role for interleukin-2 in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

The multiple origins of Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Clinical toxicity of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Toxicity management in patients receiving low-dose aldesleukin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

The role of interleukin-2 during homeostasis and activation of the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

B cell-directed therapies in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

Concise review: pancreas regeneration: recent advances and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970113-X

7 January 2021

10.1016/S2213-8587(13)70113-X

Identifiers

DOI

1 reference

19 October 2017

1 reference